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Abstract
Background: Variations in sortilin-related receptor (SORL1) expression and function have been implicated in
Alzheimers Disease (AD). Here, to gain insights into SORL1, we evaluated SORL1 expression and splicing as a
function of AD and AD neuropathology, neural gene expression and a candidate single nucleotide polymorphism
(SNP).
Results: To identify SORL1 splice variants, we scanned each of the 46 internal SORL1 exons in human brain RNA
samples and readily found SORL1 isoforms that lack exon 2 or exon 19. Quantification in a case-control series of
the more abundant isoform lacking exon 2 (delta-2-SORL1), as well as the "full-length" SORL1 (FL-SORL1)
isoform containing exon 2 showed that expression of FL-SORL1 was reduced in AD individuals. Moreover, FL-
SORL1 was reduced in cognitively intact individuals with significant AD-like neuropathology. In contrast, the
expression of the delta-2-SORL1 isoform was similar in AD and non-AD brains. The expression of FL-SORL1 was
significantly associated with synaptophysin expression while delta-2-SORL1 was modestly enriched in white
matter. Lastly, FL-SORL1 expression was associated with rs661057, a SORL1 intron one SNP that has been
associated with AD risk. A linear regression analysis found that rs661057, synaptophysin expression and AD
neuropathology were each associated with FL-SORL1 expression.
Conclusion:  These results confirm that FL-SORL1 expression declines in AD and with AD-associated
neuropathology, suggest that FL-SORL1 declines in cognitively-intact individuals with AD-associated
neuropathology, identify a novel SORL1 splice variant that is expressed similarly in AD and non-AD individuals,
and provide evidence that an AD-associated SNP is associated with SORL1 expression. Overall, these results
contribute to our understanding of SORL1 expression in the human brain.
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Background
SORL1 is a mosaic protein consisting of an amino-termi-
nal portion resembling the vacuolar protein sorting-10
(Vps10) receptor family and a carboxyl-terminal portion
having attributes of the low-density lipoprotein receptor
(LDLR) family. As such, this type-1 transmembrane pro-
tein is capable of binding ligands ranging from receptor-
associated protein (RAP) to apolipoprotein E (apoE) [1].
Recently, SORL1 has also been associated with AD at sev-
eral levels. First, SORL1 interacts with amyloid precursor
protein in the Golgi and endosomes to reduce production
of the amyloid-β (Aβ) peptide, i.e., decreased SORL1
expression results in increased Aβ production in vitro and
in a murine model in vivo [2-4]. Second, SORL1 expres-
sion is decreased in the neurons of sporadic AD patients
[5,6], consistent with its possible role in contributing to
Aβ accumulation. Furthermore, SORL1 expression is not
decreased in familial AD, suggesting that diminished
SORL1 expression is likely not a consequence of amyloid
accumulation [7]. Third, genetic variants within SORL1
have been associated with AD in many case-control series
although other studies have failed to achieve significance
[8-14]. In summary, SORL1 variants that reduce SORL1
expression or function may increase AD risk by increasing
Aβ production.
Alterations in RNA splicing have emerged as a major
mechanism of action of functional genetic variants in dis-
eases ranging from frontotemporal dementia to atypical
cystic fibrosis to myotonic dystrophy (reviewed in
[15,16]). Here, we report an analysis of SORL1 expression
and splicing in AD versus non-AD brain, reporting that
the expression of FL-SORL1 but not delta-2-SORL1 is
associated with AD and AD neuropathology, synapto-
physin expression, and an AD-associated SNP.
Methods
Human autopsy tissue
The University of Kentucky AD Center Neuropathology
Core generously provided human brain specimens from
the anterior cingulate as well as superior and middle tem-
poral gyri. Diagnoses of AD and non-AD were performed
at a consensus conference of the AD Center Neuropathol-
ogy and Clinical Cores and were based upon evaluation of
both cognitive status, i.e., Clinical Dementia Rating and
Mini-Mental State Examination (MMSE) scores, as well as
neuropathology, i.e., Braak stages which rate the extent of
neurofibrillary pathology into the neocortex and NIA-
Reagan Institute (NIA-RI) neuropathology classification,
which includes counts of both neuritic senile plaques and
neurofibrillary tangles and provides a likelihood staging
of AD neuropathological diagnosis [17,18]. The age at
death for individuals that were cognitively intact, i.e.,
non-AD, was 82 ± 9 years (mean ± SD, n = 28) while age
at death for AD individuals was 82 ± 6 (n = 29). The aver-
age post-mortem interval (PMI) for non-AD individuals
was 2.8 ± 0.8 hours (mean ± SD, n = 28) while the PMI for
AD individuals was similar at 3.4 ± 0.6 hours (n = 29).
Non-AD individuals had Mini-Mental State Examination
(MMSE) scores of 28.4 ± 1.6 (n = 28). Neuropathologic
evaluation by NIA-RI criteria revealed that among the 28
non-AD individuals, a total of 12 had findings consistent
with no likelihood of AD (age at death of 79.8 ± 12.0
(mean ± SD)), while another 10 were categorized as hav-
ing low likelihood (age at death of 84.6 ± 4.9 (n = 10),
and six as moderate likelihood (age at death of 85.0 ±
3.5). The postmortem interval for individuals in each class
was similar, i.e., 3.3 ± 0.7 (mean ± SD, n = 12), 2.4 ± 0.7
(n = 10), and 2.0 ± 0.4 (n = 6), respectively. Additionally,
the 28 non-AD, cognitively intact individuals included 20
individuals that were Braak stages 0-II, while the remain-
ing eight individuals were Braak stages III-V [18]. Neu-
ropathology in AD individuals was robust, i.e., Braak
stages were uniformly VI. The temporal lobe samples were
prepared to compare SORL1 expression in matched white
and gray matter samples. For this study, white and gray
matter were carefully dissected from the temporal lobe;
the quality of the separation was confirmed subsequently
by a comparison of the ratio of mRNAs associated with
neurons, astrocytes and oligodendrocytes, i.e., neurofila-
ment-H, GFAP, and myelin basic protein, respectively.
PCR amplification
Total RNA was extracted and converted to cDNA in one
microgram aliquots with random hexamers and reverse
transcriptase (Invitrogen, SuperScriptII) as we described
previously [19-21]. Primers that spanned SORL1 cDNA
were designed such that the splicing efficiency of each
internal exon was evaluated (Table 1). In initial screening,
pools of six AD and six non-AD cDNA samples were sub-
jected to PCR-amplification (Platinum Taq, Invitrogen)
by using each primer pair and a PCR profile consisting of
pre-incubation for 2 minutes at 94°C, followed by 30
cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 1
min (Perkin Elmer 9600). PCR products were separated
by polyacrylamide gel electrophoresis, stained with SYBR-
gold and visualized by using a fluorescence imager (Fuji
FLA-2000). PCR products of interest were identified by
direct sequencing (Davis Sequencing).
Real-time PCR
Primers were designed to amplify SORL1 that retained or
lacked exon 2 (Table 1). Briefly, PCR product correspond-
ing to FL-SORL1, i.e., the isoforms containing exon 2, was
amplified by using a sense forward primer corresponding
to sequence within exon 2 and an antisense reverse primer
corresponding to sequence within exon 4. To quantify
delta-2-SORL1, i.e., the isoform lacking exon 2, a sense
primer corresponding to the exon 1-3 junction was used
in combination with the exon 4 antisense primer (TableMolecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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Table 1: SORL1 PCR primers.
Exons Amplified Primer Primer Sequence
1-5 Exon 1 Forward GAGCTCTCTGCGAAGTCTGG
Exon 5 Reverse AAAAGGACTTGACATGTTCCTGA
4-8 Exon 4 Forward GCCCAGTACCTCTGGATCAC
Exon 8 Reverse CTCACCAAGGTGTCACTGC
7-11 Exon 7 Forward CATCTCTTGGGCAGTGAACA
Exon 11 Reverse CCACCTGGCTCCAGCACT
10-15 Exon 10 Forward CCCATCCTGTCCAAGGAGT
Exon 15 Reverse AGTAGAACCCACAGGGCAAG
14-18 Exon 14 Forward GAGTGTTTGCTGGGACACAA
Exon 18 Reverse TTTGAAGCCTGCATCTACCC
17-21 Exon 17 Forward GTGGCCCTGGACTTTGACTA
Exon 21 Reverse CAGTGTTCTTCCCCTTGTAGAAA
20-24 Exon 20 Forward TTACTGGACGGATGCCTACC
Exon 24 Reverse TTTCATCACTGTTGTCTCCACA
23-29 Exon 23 Forward TGAGCGATGAGAGAAACTGC
Exon 29 Reverse TGGAAACCGAACTCATCACA
28-32 Exon 28 Forward CGCACTTCATGGACTTTGTG
Exon 32 Reverse CCATCCTGGCAATCTTGGT
31-35 Exon 31 Forward TGTCTGCCCAATTACTACCG
Exon 35 Reverse GTGCCTTGCTGAGACACTGA0
34-40 Exon 34 Forward ATGCCCTCTGCTTCTTGTGT
Exon 40 Reverse ATGCTTCCTCGGAAGTTCAA
39-43 Exon 39 Forward ATCCCACCACCAGATATCCA
Exon 43 Reverse CCTGGTCAGGAGAGTCATACG
42-46 Exon 42 Forward ACTCCACAACAAGACGGTCA
Exon 46 Reverse CAGCTCATCGTACAGCAGGA
45-48 Exon 45 Forward CAGCACCTGATGCCTTAAAAA
Exon 48 Reverse CATATTGCAACTCAAAGTGCATCMolecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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1). Amplification reactions were 1 μM with respect to each
primer, 1× SYBR-green Master Mix (Applied Biosystems)
and the equivalent of 20 ng of template cDNA. PCR pro-
files consisted of a 10 minute pre-incubation period at
95°C followed by 40 cycles of 94°C for 30 s, 60°C for 30
s and 72°C for 30 sec (BioRad Chromo4). Primer specifi-
city was ensured by separating the PCR products via poly-
acrylamide gel electrophoresis and SYBR-gold staining as
well as melting curves at the completion of real-time PCR.
Each cDNA sample was quantified in two separate reac-
tions relative to standard curves generated with purified
and quantified PCR product standards. The copy numbers
of the SORL1 isoforms were normalized relative to the
geometric mean of the copy numbers of hypoxanthine-
guanine phosphoribosyltransferase and ribosomal pro-
tein L13A [22]. DNA samples were genotyped for
rs661057 by using unlabeled PCR primers and TaqMan
FAM and VIC dye-labeled MGB probes (Applied Biosys-
tems).
Statistical Analysis
The percentage of the delta-2-SORL1 isoform relative to
total SORL1 expression was calculated as the normalized
copy number of delta-2-SORL1 divided by the normalized
total SORL1 copy number. Differences in gene expression
as a function of AD or gray matter versus white matter
were evaluated by the two sample t-test; differences in
expression as a function of Braak stage, NIA-RI likelihood
for the neuropathological diagnosis of AD, or rs661057
were analyzed by one-way analysis of variance. The asso-
ciation of SORL1 expression with Braak stage, synapto-
physin and/or rs661057 was evaluated by using linear
regression analyses (SPSS v. 17).
FL-SORL1 Exon 2 Forward GAGGCCCAAGAGCAGTGAT
RT-PCR Primers
Delta-2-SORL1 Exon 1-3 Junction Forward CAAGGTGTACGGACAGGTGTA
Reverse Primer Exon 4 Reverse GCAGAAGTCAAACGTGATCC
Table 1: SORL1 PCR primers. (Continued)
Evaluation of SORL1 Exonic Splicing Figure 1
Evaluation of SORL1 Exonic Splicing. Inefficiently spliced exons were detected by amplifying between the indicated exons. 
The novel splice variants that were identified and confirmed by sequencing are marked with asterisks. Since these representa-
tive results are a montage of multiple experiments, the molecular weight markers are approximate.Molecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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Results
To discern SORL1 exons that are skipped with detectable
frequency, we used PCR and appropriate primer pairs to
evaluate whether each of the 46 internal SORL1 exons
were variably spliced in human brain cDNA. PCR prod-
ucts were separated by polyacrylamide gel electrophoresis
and detected by SYBR-gold staining (Figure 1). SORL1
exons were generally included within the mature mRNA
with high efficiency as most of the PCR reactions yielded
a single product of the expected size (Figure 1). However,
PCR amplification from exon 1 to exon 4 generated a 344
bp PCR product in addition to the expected 461 bp prod-
uct. Similarly, the exon 17 to 21 PCR products included
an unexpected 587 bp product in addition to the pre-
dicted 679 bp product. Direct sequencing of these unex-
pected PCR products demonstrated that the former novel
product corresponded to a SORL1 isoform lacking exon 2
while the latter corresponded to a SORL1 isoform lacking
exon 19. Since exon 2 does not alter the SORL1 reading
frame, the amino acid sequence encoded by delta-2-
SORL1 is identical to that of FL-SORL1 except for the dele-
tion of amino acids V96 through D134 (Figure 2A). In
contrast, loss of the 92 bp exon 19 leads to a shift in the
codon reading frame and a premature stop codon (Figure
2B).
Initial quantification of these novel SORL1 isoforms rela-
tive to the FL- SORL1 isoform suggested that delta-2-
SORL1 expression represented 1-5% of total SORL1
expression while delta-19-SORL1 expression was gener-
ally less than 1% of total SORL1 expression (Figure 3,
Table 2, data not shown). Hence, we focused further anal-
yses upon the more abundant delta-2-SORL1 isoform as
well as FL-SORL1. Expression of delta-2-SORL1 tended to
parallel that of FL-SORL1 (Figure 3A). Evaluation of
expression as a function of AD found that FL-SORL1 but
not delta-2-SORL1 was decreased in AD brain samples
(Figure 3B, C, Table 2). Total SORL1 expression was also
significantly decreased in AD brain samples, confirming
prior results [5,7], and reflecting that most of the SORL1
mRNA is FL-SORL1 (Table 2). Since the abundance of
delta-2-SORL1 was relatively unchanged between AD and
non-AD while FL-SORL1 was decreased, the percentage of
delta-2-SORL1 was significantly increased in the AD sam-
ples (Table 2).
In considering these results further, we recognized that
while the non-AD individuals were all cognitively intact
within a year of their death, e.g., their MMSE scores were
28.4 ± 1.6 (n = 28, range 24-30), a subset of these individ-
uals had significant AD-associated neuropathology at
autopsy. Hence, we explored whether the AD-associated
decline in SORL1 expression correlated with neuropathol-
ogy. First, we considered SORL1 expression relative to
Braak staging, which reflects the severity of neurofibrillary
pathology in the medial temporal lobe structure and
extension into the cortex. Eight of the 28 non-AD individ-
uals had significant AD-associated neuropathology, i.e.,
Braak stages of III, IV or V. When SORL1 expression was
evaluated as a function of Braak stage (Figure 4, Table 3),
individuals who were cognitively intact but had moderate
AD-like pathology (Braak stages of III-V) were found to
have SORL1 expression levels more similar to the AD indi-
viduals (Braak VI) than the cognitively intact individuals
with little AD-like pathology (Braak stages 0-II). Hence,
even among cognitively intact individuals, the expression
of FL-SORL1 but not delta-2-SORL1 was reduced as the
severity of AD-like neuropathology increased. We addi-
tionally evaluated SORL1 expression as a function of NIA-
RI criteria, which includes both CERAD neuritic plaque
scores and Braak staging. With these criteria, 22 of the
non-demented individuals had neuropathology consist-
ent with no or low likelihood of AD, while six had suffi-
cient pathology to rank as intermediate to high AD
probability, based solely on neuropathology. The expres-
sion of FL-SORL1 but not delta-2-SORL1 was again signif-
icantly decreased in the intermediate-high AD likelihood
individuals, relative to the individuals with no-low likeli-
hood of AD (Table 4). Hence, the expression of FL-SORL1
but not delta-2-SORL1 is decreased as a function of AD
neuropathology.
We hypothesized that delta-2-SORL1 expression is
enriched in glia because SORL1 expression was reported
to be reduced only in neurons in AD and delta-2-SORL1
was not reduced in AD [5]. To assess this possibility, we
quantified FL-SORL1 and delta-2- SORL1 in matched gray
and white matter samples carefully dissected from five
non-AD brains. We found that the percentage of delta-2-
SORL1 was significantly greater in white matter than gray
matter, i.e., 5.0 ± 0.7% versus 3.8 ± 0.5%, respectively
(mean ± SD, n = 5, p = 0.006), consistent with the possi-
bility that the proportion of the delta-2-SORL1 isoform
varies as a function of cell type. We also evaluated SORL1
expression by using a linear regression model that
included the expression of synaptophysin, which encodes
a synaptic vesicle protein, as well as AD neuropathology,
as reflected by Braak stage. We found that the expression
of FL-SORL1 was associated with both Braak stage and
synaptophysin expression (Figure 5, p = 0.015 and
<0.001, respectively, adjusted r2 = 0.347) while delta-2-
SORL1 was not significantly associated with either factor
(adjusted r2 = 0.036, data not shown). In summation, the
decline in FL-SORL1 expression with Braak stage is signif-
icant even when synaptophysin expression is considered
as well.
Lastly, we evaluated whether rs661057 was associated
with FL-SORL1 expression or the proportion of delta-2-
SORL1; we chose this SNP because rs661057 is withinMolecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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Sequence of SORL1 Isoforms Figure 2
Sequence of SORL1 Isoforms. The nucleotide and protein sequence of FL-SORL1 as well as sequences corresponding to 
each of the novel isoforms is shown. Figure 2A (upper panel) depicts FL-SORL1 nucleotide and protein sequence beginning 
with the ATG translation start site in exon 1 through exon 3. Exon 2 is marked in red font. The nucleotide and protein 
sequence corresponding to delta-2-SORL1, i.e., loss of amino acids V96-D134, is shown in the lower panel, with the exon 1-3 
junction indicated by red font. Figure 2B shows FL-SORL1 nucleotide and protein sequence from exon 18-20 (upper panel) 
with exon 19 marked in red font. The lower panel shows the nucleotide and protein sequence corresponding to delta-19-
SORL1, i.e., a novel peptide sequence encoded by an out-of-frame exon 20, followed by a premature stop codon. The exon 18-
20 junction is indicated by red font and the novel peptide sequence is shown in blue font.
A. Exon 1-2-3 Nucleotide and Protein Sequence 
atggcgacacggagcagcaggagggagtcgcgactcccgttcctattcaccctggtcgca
 M  A  T  R  S  S  R  R  E  S  R  L  P  F  L  F  T  L  V  A 
ctgctgccgcccggagctctctgcgaagtctggacgcagaggctgcacggcggcagcgcg
 L  L  P  P  G  A  L  C  E  V  W  T  Q  R  L  H  G  G  S  A 
cccttgccccaggaccggggcttcctcgtggtgcagggcgacccgcgcgagctgcggctg
 P  L  P  Q  D  R  G  F  L  V  V  Q  G  D  P  R  E  L  R  L 
tgggcgcgcggggatgccaggggggcgagccgcgcggacgagaagccgctccggaggaaa
 W  A  R  G  D  A  R  G  A  S  R  A  D  E  K  P  L  R  R  K 
cggagcgctgccctgcagcccgagcccatcaaggtgtacggacaggttagtctgaatgat
 R  S  A  A  L  Q  P  E  P  I  K  V  Y  G  Q  V  S  L  N  D 
tcccacaatcagatggtggtgcactgggctggagagaaaagcaacgtgatcgtggccttg
 S  H  N  Q  M  V  V  H  W  A  G  E  K  S  N  V  I  V  A  L 
gcccgagatagcctggcattggcgaggcccaagagcagtgatgtgtacgtgtcttacgac
 A  R  D  S  L  A  L  A  R  P  K  S  S  D  V  Y  V  S  Y  D 
tatggaaaatcattcaagaaaatttcagacaagttaaactttggcttgggaaataggagt
 Y  G  K  S  F  K  K  I  S  D  K  L  N  F  G  L  G  N  R  S 
gaagctgttatcgcccagttctaccacagccctgcggacaacaagcgg 
 E  A  V  I  A  Q  F  Y  H  S  P  A  D  N  K  R 
 
Exon 1-3 (Lacking exon 2) Nucleotide and Protein Sequence 
atggcgacacggagcagcaggagggagtcgcgactcccgttcctattcaccctggtcgca
 M  A  T  R  S  S  R  R  E  S  R  L  P  F  L  F  T  L  V  A 
ctgctgccgcccggagctctctgcgaagtctggacgcagaggctgcacggcggcagcgcg
 L  L  P  P  G  A  L  C  E  V  W  T  Q  R  L  H  G  G  S  A 
cccttgccccaggaccggggcttcctcgtggtgcagggcgacccgcgcgagctgcggctg
 P  L  P  Q  D  R  G  F  L  V  V  Q  G  D  P  R  E  L  R  L 
tgggcgcgcggggatgccaggggggcgagccgcgcggacgagaagccgctccggaggaaa
 W  A  R  G  D  A  R  G  A  S  R  A  D  E  K  P  L  R  R  K 
cggagcgctgccctgcagcccgagcccatcaaggtgtacggacaggtgtacgtgtcttac
 R  S  A  A  L  Q  P  E  P  I  K  V  Y  G  Q  V  Y  V  S  Y 
gactatggaaaatcattcaagaaaatttcagacaagttaaactttggcttgggaaatagg
 D  Y  G  K  S  F  K  K  I  S  D  K  L  N  F  G  L  G  N  R 
agtgaagctgttatcgcccagttctaccacagccctgcggacaacaagcgg 
 S  E  A  V  I  A  Q  F  Y  H  S  P  A  D  N  K  R 
 
 
B. Exon 18-19-20 Nucleotide and Protein Sequence 
cgcctctgtttgaatggaagcacagggcaagaggtgatcatcaattctggcctggagaca
 R  L  C  L  N  G  S  T  G  Q  E  V  I  I  N  S  G  L  E  T 
gtagaagctttggcttttgaacccctcagccagctgctttactgggtagatgcaggcttc
 V  E  A  L  A  F  E  P  L  S  Q  L  L  Y  W  V  D  A  G  F 
aaaaagattgaggtagctaatccagatggcgacttccgactcacaatcgtcaattcctct
 K  K  I  E  V  A  N  P  D  G  D  F  R  L  T  I  V  N  S  S 
gtgcttgatcgtcccagggctctggtcctcgtgccccaagagggggtgatgttctggaca
 V  L  D  R  P  R  A  L  V  L  V  P  Q  E  G  V  M  F  W  T 
gactggggagacctgaagcctgggatttatcggagcaatatggatggttctgctgcctat
 D  W  G  D  L  K  P  G  I  Y  R  S  N  M  D  G  S  A  A  Y 
cacctggtgtctgaggatgtgaagtggcccaatggcatctctgtggacgaccagtggatt
 H  L  V  S  E  D  V  K  W  P  N  G  I  S  V  D  D  Q  W  I 
tactggacggatgcctacctggagtgcatagagcggatcacgttcagtggccagcagcgc
 Y  W  T  D  A  Y  L  E  C  I  E  R  I  T  F  S  G  Q  Q  R 
tctgtcattctggacaacctcccgcacccctatgccattgctgtctttaaggcgg 
 S  V  I  L  D  N  L  P  H  P  Y  A  I  A  V  F  K  A 
 
Exon 18-20 (Lacking exon 19) Nucleotide and Protein Sequence
cgcctctgtttgaatggaagcacagggcaagaggtgatcatcaattctggcctggagaca
 R  L  C  L  N  G  S  T  G  Q  E  V  I  I  N  S  G  L  E  T 
gtagaagctttggcttttgaacccctcagccagctgctttactgggtagatgcaggcttc
 V  E  A  L  A  F  E  P  L  S  Q  L  L  Y  W  V  D  A  G  F 
aaaaagattgagggtgatgttctggacagactggggagacctgaagcctgggatttatcg
 K  K  I  E  G  D  V  L  D  R  L  G  R  P  E  A  W  D  L  S 
gagcaatatggatggttctgctgcctatcacctggtgtctga 
 E  Q  Y  G  W  F  C  C  L  S  P  G  V  - Molecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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intron 1 of SORL1 and has been associated with AD in
some populations [8]. Rs661057 per se was significantly
associated with the expression of both FL-SORL1 and
delta-2-SORL1 (Table 5); interestingly, this association
was the result of rs661057 heterozygotes having lower
SORL1 expression. However, rs661057 was not associated
significantly with the percentage of SORL1 that was
expressed as delta-2-SORL1 and hence this SNP appeared
associated with SORL1 expression per se in these samples.
Further evaluation of the data indicated that the rs661057
heterozygotes were over-represented among the individu-
als with higher Braak stages (Figure 6). To discern whether
the apparent rs661057 association with SORL1 expres-
sion was independent of AD neuropathology and synap-
tophysin expression, we analyzed FL-SORL1 expression
by using a linear regression model that included rs661057
genotype, synaptophysin expression and Braak stage;
since FL-SORL1 expression was similar for individuals
with moderate and high Braak stages, these two categories
were combined to optimize statistical power. This analysis
found that the inclusion of rs661057 produced a more
robust model of the data than Braak stage and synapto-
Quantitation of FL-SORL1 and Delta-2-SORL1 in AD and non-AD Brain Figure 3
Quantitation of FL-SORL1 and Delta-2-SORL1 in AD and non-AD Brain. Real time PCR quantification of each iso-
form shows that FL-SORL1 and delta-2-SORL1 vary in parallel (A) (r2 = 0.371, p < 0.001, AD individuals represented as filled 
circles, non-AD as open circles). FL-SORL1 was decreased in AD relative to non-AD individuals (B) while delta-2-SORL1 was 
similar in AD and non-AD individuals (C). Delta-2-SORL1 as a percentage of total SORL1 expression was increased in AD indi-
viduals (D).Molecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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physin alone, with an adjusted r2 of 0.461. Braak stage,
rs661057, and synaptophysin were each significantly
associated with FL-SORL1 (Table 6).
Discussion
The primary findings of this report are four-fold. First, the
expression of FL-SORL1 and total SORL1 is reduced in the
AD brain, confirming prior reports [5,6]. Second, the
expression of FL-SORL1 and total SORL1 is decreased in
cognitively intact individuals with moderate AD neuropa-
thology, consistent with the possibility that SORL1
declines early in the disease. Third, we report the identifi-
cation of novel SORL1 isoforms lacking exons 2 or 19.
Quantification of the delta-2-SORL1 isoform reveals that
this isoform is expressed at similar levels in AD and non-
AD individuals. Lastly, we interpret our data as suggesting
a model for SORL1 expression that includes AD neuropa-
thology, synaptophysin expression, and rs661057, an AD-
associated SNP. Overall, these results provide insight into
variables associated with SORL1 expression and show that
exon skipping is a rare event in SORL1 mRNA.
Since the first report of reduced SORL1 expression in AD
neurons in 2004 [5], a predominant theory has emerged
that a reduction in functional SORL1 contributes to
increased Aβ and, thereby, increased AD risk [2,6-8]. Here,
we confirm prior results showing that SORL1 expression
is generally reduced in AD [5,6]. Additionally, we report
that SORL1 expression is reduced in individual that were
cognitively intact but yet had moderate AD-like pathol-
ogy, and hence could represent "preclinical" AD subjects
[23,24]. This result is similar to that of Sager et al. [6] who
reported that SORL1 expression in individuals with mild
cognitive impairment (MCI) was quite variable such that
SORL1 expression in some MCI individuals was similar to
Table 2: Expression of SORL1 isoforms in AD versus non-AD 
brains.
SORL1 Isoform AD Diagnosis N Mean ± SE P Value
Total SORL1 Non-AD 28 1.978 ± 0.136 0.028
AD 29 1.537 ± 0.140
FL-SORL1 Non-AD 28 1.935 ± 0.134 0.025
AD 29 1.493 ± 0.138
Delta-2-SORL1 Non-AD 28 0.043 ± 0.003 0.868
AD 29 0.044 ± 0.003
Delta-2-SORL1 (%) Non-AD 28 2.29 ± 0.13 <0.001
AD 29 3.02 ± 0.14
Table 3: Expression of SORL1 isoforms relative to Braak stage.
SORL1 ISOFORM Braak N Mean ± SE P Value*
Total SORL1 0-II 20 2.167 ± 0.150 0.009
III-V 8 1.507 ± 0.228 0.031*
VI 29 1.537 ± 0.140 0.004*
FL-SORL1 0-II 20 2.121 ± 0.150 0.008
III-V 8 1.470 ± 0.222 0.031*
VI 29 1.493 ± 0.138 0.003*
Delta-2-SORL1 0-II 20 0.046 ± 0.003 0.339
III-V 8 0.037 ± 0.006
VI 29 0.044 ± 0.003
Delta-2-SORL1 (%) 0-II 20 2.26 ± 0.16 0.002
III-V 8 2.48 ± 0.15 0.454*
VI 29 3.02 ± 0.14 0.001*
For each isoform, the initial p value is the overall ANOVA p value, 
while the p values marked with asterisks refer to LSD post-hoc 
comparisons with the Braak 0-II group.
Table 4: Expression of SORL1 isoforms in human brain as a 
function of NIA-RI neuropathology classification.
SORL1 Isoform NIA-RI N Mean ± SE P Value
Total SORL1 Zero-Low 22 2.023 ± 0.151 0.033
Mod-High 35 1.584 ± 0.128
FL-SORL1 Zero-Low 22 1.980 ± 0.150 0.031
Mod-High 35 1.540 ± 0.126
Delta-2-SORL1 Zero-Low 22 0.043 ± 0.003 0.826
Mod-High 35 0.044 ± 0.003
Delta-2-SORL1 (%) Zero-Low 22 2.25 ± 0.15 0.001
Mod-High 29 2.93 ± 0.13Molecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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Quantitation of FL-SORL1 and Delta-2-SORL1 as a Function of Braak Stage Figure 4
Quantitation of FL-SORL1 and Delta-2-SORL1 as a Function of Braak Stage. The expression of FL-SORL1 was 
reduced in cognitively intact individuals with a Braak stage indicative of some AD neuropathology relative to cognitively intact 
individuals with little neuropathology (A). In contrast, the expression of delta-2-SORL1 was similar among the groups (B).Molecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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normal individuals while SORL1 expression in other MCI
individuals was reduced to levels similar to those seen in
AD. Hence, the decreased SORL1 expression that we
observed here in cognitively intact individuals with mod-
erate AD neuropathology is suggestive that declines in
SORL1 expression presage the onset of AD dementia.
To investigate the role of SORL1 splicing in SORL1 varia-
tion, we evaluated each of the SORL1 exons to identify
those that are frequently not present within mature
SORL1 mRNA. This led to the identification of the delta-
2-SORL1 and delta-19-SORL1 isoforms. The former was
modestly enriched in white matter relative to gray matter,
consistent with its lack of association with synaptophysin
expression. The latter was present at levels too low for reli-
able quantitation in many of the samples, and hence we
were unable to compare expression among groups. The
function of the proteins encoded by these novel isoforms
is not currently known. Delta-2-SORL1 encodes a SORL1
protein variant that lacks amino acids V96-D134. The
functional consequences of loss of this portion of the
Vps10p domain are not known but could impact sorting
properties of the protein. The loss of exon 19 in delta-19-
SORL1 introduces a codon frameshift, resulting in an iso-
form that encodes the normal SORL1 protein until amino
acid 857, followed by a novel 29 amino acid sequence and
a premature stop codon after amino acid 886 (Figure 2).
Hence, this truncated receptor is predicted to contain the
intact Vsp10p domain, as well as the first two LDLR class
B repeats but lack several LDLR class A repeats, the
fibronectin type III domain, the transmembrane domain
and the cytosolic tail. Although the function of this trun-
cated, delta-19-encoded soluble receptor is not yet clear,
Jacobsen et al. evaluated a SORL1 minireceptor that con-
sisted of the 731 amino-terminal SORL1 amino acids and
found that this truncated receptor bound RAP but not
apoE [1]. A similar function may be found for delta-19-
SORL1. In summation, while the function of protein
encoded by delta-2-SORL1 is unclear, we speculate that
the protein encoded by delta-19-SORL1 may represent a
dominant negative form of SORL1 that binds some
SORL1 ligands, but, since it lacks the cytosolic tail, will
not modulate their sorting. If either of these SORL1 vari-
ants represent loss of function for SORL1, they may con-
tribute to increased Aβ production and, thereby, AD risk.
Quantitation of FL-SORL1 as a function of synaptophysin expression and Braak stage Figure 5
Quantitation of FL-SORL1 as a function of synaptophysin expression and Braak stage. Individuals that have Braak 
stages that are low (0-II, open circles), moderate (Braak III-V, green circles) or high (VI, black-filled circles) are indicated. Linear 
regression analyses found that both synaptophysin and Braak stage (two degrees of freedom) were significantly associated with 
SORL1 expression, (p < 0.001 and p = 0.015, respectively). Synaptophysin expression showed only a slight trend towards 
decreased expression with Braak stage, which did not achieve significance (p = 0.55, ANOVA)Molecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
Page 11 of 13
(page number not for citation purposes)
In evaluating factors that associate with SORL1 expres-
sion, we arrived at a model that includes (i) AD-associated
neuropathology, as reflected by Braak stage, (ii) neuronal
gene expression, as reflected by synaptophysin expression,
and (iii) a SORL1 intron 1 SNP, rs661057, that has been
associated with AD in at least some series [8]. The associ-
ation between synaptophysin and SORL1 expression
likely reflects neuronal expression of SORL1 [5]. The
mechanisms underlying the association between SORL1
expression and Braak stage or rs661057 are unknown.
Regarding rs661057, individuals that are heterozygous for
this SNP had lower SORL1 expression than individuals
homozygous for the major or minor allele. Hence,
rs661057 would appear to show homozygote dominance,
with an unclear underlying mechanism. Consideration of
the association between rs661057 and AD does not clarify
this situation (meta-analysis at http://www.alzgene.org/
,[25]) because the SNP seems to show a genotype dose
dependent association with AD. Evaluation of the wide-
spread reproducibility of rs661057 association with
SORL1 expression in other studies will be of interest to the
field.
Conclusion
In summary, we confirmed that SORL1 expression is
reduced in the AD brain. Moreover, SORL1 expression
was decreased as a function of AD-associated neuropa-
Quantitation of FL-SORL1 as a function of rs661057 and  Braak stage Figure 6
Quantitation of FL-SORL1 as a function of rs661057 
and Braak stage. Individuals that have Braak stages that are 
low (0-II, open circles), moderate (Braak III-V, green circles) 
or high (VI, black-filled circles) are indicated.
Table 5: Expression of SORL1 isoforms in human brain as a 
function of rs661057 genotype.
SORL1 ISOFORM Rs661057 N Mean ± SE P Value*
Total SORL1 T/T 18 2.249 ± 0.196 <0.001
T/C 30 1.383 ± 0.086 <0.001*
C/C 8 2.081 ± 0.295 0.552*
FL-SORL1 T/T 18 2.199 ± 0.195 <0.001
T/C 30 1.344 ± 0.084 <0.001*
C/C 8 2.033 ± 0.292 0.553*
Delta-2-SORL1 T/T 18 0.050 ± 0.003 0.017
T/C 30 0.039 ± 0.002 0.007*
C/C 8 0.048 ± 0.007 0.706*
Delta-2-SORL1 (%) T/T 18 2.36 ± 0.20 0.072
T/C 30 2.88 ± 0.14
C/C 8 2.46 ± 0.28
For each isoform, the initial p value is the overall ANOVA p value, 
while the p values marked with asterisks refer to LSD post-hoc 
comparisons with the rs661057 T/T group.
Table 6: Estimated Marginal Means for FL-SORL1 Expression.
Variable Estimated Marginal
Mean ± SE
P Value
Braak Stage
Low (0-II) 2.058 ± 0.127 0.046
High (III-VI) 1.706 ± 0.109
Rs661057
T/T 2.091 ± 0.137 0.012
T/C 1.557 ± 0.112
C/C 1.998 ± 0.194
These data reflect the values for the indicated parameter with 
synaptophysin expression normalized to 5.48. Synaptophysin 
expression was also significantly associated with FL-SORL1 
expression (p < 0.001).Molecular Neurodegeneration 2009, 4:46 http://www.molecularneurodegeneration.com/content/4/1/46
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thology prior to dementia, suggesting that the SORL1
reduction precedes conversion to AD. The exons of SORL1
were generally included within the mature message with
high efficiency, with only exons 2 and 19 being skipped at
detectable levels. Delta-2-SORL1 was modestly enriched
in white matter and unchanged in AD. Lastly, Braak stage,
synaptophysin expression, and rs661057 were all found
to be associated with SORL1 expression.
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